Tyligand
Latest round
- Series A
Last raised
- Jul 2023
Total raised
- $20M
Investors
- 13
About Tyligand
Based in Shanghai, China and established in 2018, Tyligand is a medicial company that provides tumor immunotherapy drug. Yantao Zhang, the co-founder and chairman of the company, was the Chief Scientist of Eli Lilly's Small Molecule Design and Development Department, the first Managing Director of Lilly China R&D Center, and Vice President of Lilly Global Collaborative Research and Development Asia Pacific. The company integrates unique scientific insights into target proteins and rich experience in medicinal chemistry, and the company is committed to the development of novel small molecule drugs for tumors and immune diseases. The company has established a unique antitumor molecular pipeline, with indications covering lung cancer, colorectal cancer, hormone-driven tumors, and a variety of solid tumors. In the future, the company will promote the transformation of the company's pipeline to the clinical phase, including the Phase II clinical trial of Oralpristone in China, the preclinical research and IND application of 3 innovative molecules, and the compound optimization of several First-in-class research projects.
Who invested in Tyligand
13 investors across 4 rounds
See all investors in Tyligand
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Tyligand
Who invested in Tyligand?
Tyligand has 13 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Tyligand raised?
Tyligand has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Tyligand last raise money?
Tyligand's most recent round on record is a Series A, in Jul 2023.
What does Tyligand do?
Based in Shanghai, China and established in 2018, Tyligand is a medicial company that provides tumor immunotherapy drug.
Where is Tyligand headquartered?
Tyligand is headquartered in Shanghai, China.
Which VCs invest in companies like Tyligand?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Tyligand's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Tyligand? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.